MIRUM PHARMACEUTICALS, INC. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 24.46 USD | -0.12% |
|
+2.73% | -17.14% |
| Sales 2024 * | 316M 25.33B | Sales 2025 * | 418M 33.49B | Capitalization | 1.15B 92.01B |
|---|---|---|---|---|---|
| Net income 2024 * | -58M -4.64B | Net income 2025 * | 18M 1.44B | EV / Sales 2024 * | 2.75 x |
| Net cash position 2024 * | 280M 22.44B | Net cash position 2025 * | 360M 28.8B | EV / Sales 2025 * | 1.89 x |
| P/E ratio 2024 * |
-21.6
x | P/E ratio 2025 * |
66.6
x | Employees | 264 |
| Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 95.88% |
More Fundamentals
* Assessed data
More news
Latest transcript on Mirum Pharmaceuticals, Inc.
More recommendations
More press releases
More news
| 1 day | -0.12% | ||
| 1 week | +2.73% | ||
| Current month | -2.63% | ||
| 1 month | -1.85% | ||
| 3 months | -6.53% | ||
| 6 months | -11.18% | ||
| Current year | -17.14% |
1 week
23.14
25.01
1 month
23.1426.61
Current year
23.1430.29
1 year
23.1435.56
3 years
12.8235.56
5 years
6.5135.56
10 years
6.5135.56
| Managers | Title | Age | Since |
|---|---|---|---|
| Founder | 45 | 06/05/18 | |
Michael Grey
FOU | Founder | 71 | 06/05/18 |
Peter Radovich
PSD | President | 46 | 27/04/20 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Timothy Walbert
BRD | Director/Board Member | 57 | 04/04/23 |
Michael Grey
FOU | Founder | 71 | 06/05/18 |
Patrick Heron
BRD | Director/Board Member | 53 | 06/11/18 |
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 0.04% | 0 M€ | 0.00% | - | |
| 0.04% | 0 M€ | 0.00% | - |
| Date | Price | Change | Volume |
|---|---|---|---|
| 26/04/24 | 24.46 | -0.12% | 268,335 |
| 25/04/24 | 24.49 | +1.96% | 817,338 |
| 24/04/24 | 24.02 | -1.64% | 317,121 |
| 23/04/24 | 24.42 | +1.03% | 423,071 |
| 22/04/24 | 24.17 | +1.51% | 254,735 |
Delayed Quote Nasdaq, April 26, 2024 at 09:00 pm
More quotes
Mirum Pharmaceuticals, Inc. is a biopharmaceutical company. The Company is focused on the identification, acquisition, development and commercialization of therapies for debilitating rare and orphan diseases. It has three medicines: LIVMARLI (maralixibat) oral solution (Livmarli), Cholbam (cholic acid) capsules, and Chenodal (chenodiol) tablets. Livmarli is an orally administered, minimally-absorbed ileal bile acid transporter (IBAT) inhibitor (IBATi) that is used for the treatment of cholestatic pruritus in patients with Alagille syndrome (ALGS) in the United States and various other countries and for cholestatic pruritus in patient with progressive familial intrahepatic cholestasis (PFIC) in the United States. Cholbam is used for the treatment of bile acid synthesis disorders due to single enzyme deficiencies and adjunctive treatment of peroxisomal disorders. It is also advancing its product candidate, volixibat, for the treatment of adult patients with cholestatic liver diseases.
Calendar
01/05/2024
- Q1 2024 Earnings Release (Projected)
Related indices
Trading Rating
Investor Rating
ESG Refinitiv
D+
Sell
Buy
Mean consensus
BUY
Number of Analysts
11
Last Close Price
24.46
USD
Average target price
48.91
USD
Spread / Average Target
+99.96%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -17.14% | 1.15B | |
| +1.51% | 42.75B | |
| +49.22% | 41.61B | |
| +8.57% | 41.34B | |
| -12.36% | 26.59B | |
| +8.92% | 25.49B | |
| -25.13% | 18.12B | |
| +29.17% | 12.24B | |
| -3.12% | 11.76B | |
| +6.35% | 11B |
- Stock Market
- Equities
- MIRM Stock
